Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They primarily conduct research and development in the area of metabolic and fibrotic diseases. The company's product portfolio includes several brands and drugs, and the operations are conducted on a global level, with the largest presence in North America and the Nordic region. The headquarters are located in Hørsholm, Denmark.
I dagens Morgenbørs ser vi ind i et positivt futuresmarked med tro på en mulig fredsaftale i Mellemøsten. Herhjemme er der stor regnskabsdag med regnskaber fra bl.a. Novo Nordisk, Vestas, Pandora, Demant, Ørsted og Ambu.
Gubra today announced that its partner Boehringer Ingelheim plans to initiate Phase 2 development of BI 3034701 in mid-2026. BI 3034701 is a potential first-in-class triple GLP-1, GIP and NPY2 receptor agonist peptide for obesity, originating from Gubra's peptide discovery platform. The advancement provides further validation of Gubra's platform capabilities - particularly its ability to engineer differentiated, first-in-class peptide candidates within obesity that attract continued development investment from top-tier pharma partners.
Gubra ventes at offentliggøre sin handelsopdatering for Q1 2026 den 6. maj 2026. Den 12. maj kl. 13.00 vil selskabets CFO Kristian Borbos og IR og Strategy Lead Emma Jappe Lange præsentere kvartalsopdateringen og svare på spørgsmål fra investorer i et live-event.
In connection with AbbVie reporting positive topline results from a Phase 1 trial for ABBV-295, Gubra’s out-licensed long-acting amylin analogue, we hosted a live event with CFO Kristian Borbos and IR & Strategy Lead Emma Jappe Lange from Gubra.
On the 9th of March AbbVie reported positive topline results from the multiple ascending dose (MAD) portion of the Phase 1 trial for ABBV-295, Gubra’s out-licensed long-acting amylin analog.
I dagens Morgenbørs ser vi ind i et store fald på futures fronten, oliepriser har krydset 100 og øget nervøsitet omkring finansiering af AI udbygningen. Herhjemme, fokus på bl.a. Novo, Zealand, høreapparatsproducenterne.
I dagens Morgenbørs ser vi ind i europæiske futures der indikerer et re-bound ovenpå Trumps kommentarer omkring længde på konflikten. Herhjemme, fokus på blandt andet Novo, Gubra og taberne på stigende oliepris.
AbbVie today reported positive topline results from the multiple ascending dose (MAD) portion of the Phase 1 trial for ABBV-295, Gubra's out-licensed long-acting amylin analog.
The study demonstrated dose-dependent weight loss ranging from -7.75% to -9.79% at week 12 for weekly dosing cohorts, and -7.86% to -9.73% at week 13 for less frequent dosing regimens (every other week and monthly after week 5), compared to approximately -0.25% for placebo.
2025 was a pivotal year for Gubra, with revenue of DKK 2.6bn and operating profit of DKK 2.2bn, driven by the landmark out-licensing agreement with AbbVie for the long-acting amylin analogue ABBV-295, with USD 350m in upfront payment, and DKK 1.1bn well-positioned to drive further development
2025 also marked the beginning of a broader transformation evolving from an obesity-focused biotech into a broader, more diversified life science company, with the new Ventures unit set to incubate focused companies in therapeutic areas beyond the core pipeline, with the first venture planned for H2 2026. The company has announced ambitions to establish new flagship therapeutic areas beyond obesity by 2030, and the CRO platform is expanding into new service areas, including sarcopenia and women’s health.
